By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#97 – Peter Hotez, M.D., Ph.D.: COVID-19: transmissibility, vaccines, risk reduction, and treatment
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:11 – 4:51
Episode Setup and Why This Conversation Is Happening Now
Peter Attia introduces Dr. Peter Hotez and explains why he moved up the interview as the situation changed. He previews the topics and says updates will come in shorter, more frequent episodes with free show notes.
- •Hotez's roles as vaccine scientist, pediatrician and coronavirus expert
- •Attia says he miscalculated the scale of the outbreak in early 2020
- •Information is changing so fast that the episode may be background within a week
- •Topics previewed include the virus, spread, treatment options, vaccine timelines and convalescent serum
- •Coronavirus show notes will be free for all listeners
- 4:51 – 7:24
SARS-CoV-2 vs. COVID-19 and Three Coronavirus Pandemics
Hotez explains that COVID-19 is the disease and SARS-CoV-2 is the virus, comparing it to AIDS and HIV. He places it as the third coronavirus pandemic of the 21st century, after SARS in 2003 and MERS in 2012.
- •COVID-19 is the WHO-designated disease name; SARS-CoV-2 is the causative virus
- •Coronaviruses were once considered minor, mostly causing upper respiratory infections in kids
- •SARS 1 emerged in 2003 and MERS in 2012
- •A new coronavirus pandemic has arrived every decade this century, which bears on vaccine prioritization
- 7:24 – 12:26
Why Both Lethality and Transmissibility Make This Virus Dangerous
Hotez contrasts SARS 1 and MERS, which made people very sick and burned out, with SARS-2, which is serious for certain groups while many others spread it. He describes the vulnerable groups, including healthcare workers, and the strain on the healthcare workforce.
- •SARS 2 is high in both lethality and transmissibility
- •Kids, adolescents and young adults spread it without getting very sick
- •Those over 70 and people with diabetes, hypertension or heart disease are most at risk
- •Healthcare workers get sicker than expected, as seen in Wuhan
- •Attia notes that losing healthcare workers has a nonlinear effect, and Hotez adds first responders
- 12:26 – 15:59
US Testing Failures and the Cost of Delayed Detection
The discussion turns to the US testing shortfall and how long undetected transmission worsens outcomes. Hotez cites Wuhan versus Guangdong and warns hospitals could be inundated in a couple of weeks.
- •Promises on test availability keep shifting
- •Cities that let transmission run for weeks, such as Wuhan, were overwhelmed
- •Guangdong detected spread after a week and had about 20 ICU patients
- •US transmission probably began in mid-February and went undetected
- •Large-scale testing in the next week could still let communities intervene
- 15:59 – 19:44
Convalescent Serum as a Low-Cost Intervention
Hotez describes the idea, pushed by Arturo Casadevall, of collecting antibodies from recovered patients to treat the sick and protect healthcare workers. He and Attia discuss apheresis, blood banks, regulatory guidance and how many people one donor could help.
- •Antibody-rich serum from recovered patients could be a treatment and prophylaxis
- •Historical precedent includes the 1918 flu and experiences with SARS and MERS
- •Blood banks and FDA/CBER guidance would be needed, and apheresis looks required
- •Treatment may need roughly one donor per patient, while prophylaxis could cover dozens or even 100 people
- •Casadevall favors a federal task force to standardize the approach
- 19:44 – 20:20
Remdesivir and Antiviral Prospects
Attia asks about Remdesivir, the Gilead drug originally developed for Ebola. Hotez says he hasn't seen the data, that a clinical trial is needed, and that antivirals will move faster than vaccines.
- •Remdesivir is being used on compassionate exemption
- •Hotez hasn't seen efficacy numbers
- •A clinical trial and possibly combination therapy would be required
- •Antivirals should come faster than vaccines
- 20:20 – 27:52
Vaccine Timelines, Immune Enhancement, and Hotez's Stalled Vaccine
Hotez explains why vaccines face the highest safety bar and why coronavirus vaccines carry the risk of immune enhancement, as seen with the 1960s RSV vaccine. He describes his lab's receptor binding domain vaccine, already manufactured but without funding for clinical trials.
- •Vaccine development typically takes one to three years through phases I to III
- •Rino Rappuoli has proposed running steps in parallel to speed things up
- •Immune enhancement appeared with the RSV vaccine and in animal studies of SARS vaccines
- •A receptor-binding-domain vaccine avoided enhancement in animals
- •His team has not raised money to start clinical trials and invites contact by email
- 27:52 – 31:33
ACE2 Receptor, Organ Damage, and Modes of Transmission
Attia asks about the ACE2 receptor and lung pathology. Hotez says the receptor is also in the gut and endothelium, which may explain heart injury and GI presentations, and that transmission routes remain uncertain.
- •ACE2 is found in the lungs, intestines and endothelial cells
- •Patients show acute myocardial injury alongside ARDS, and it is unclear how they relate
- •About 10% of some Wuhan patients presented with GI symptoms, and misdiagnosis infected healthcare workers
- •Paul Offit wonders whether the GI route matters, given the cruise ship outbreaks
- •Droplet contact is important, while fecal-oral and true airborne spread are unknown
- 31:33 – 36:44
Surface Survival, R-Naught, and Case Fatality
Attia raises a New England Journal of Medicine study on how long the virus survives on surfaces. Hotez uses it to explain R-naught and compares transmissibility and fatality with flu and measles.
- •Virus remained viable for about 72 hours on plastic, 48 on cardboard, 24 on steel and 8 to 24 on copper
- •Hotez cites an R-naught of roughly 2.24 to 3.58, versus about 1.2 to 1.3 for seasonal flu
- •Measles is far higher at 12 to 18
- •Case fatality is cited at 0.6 to 3.4%, with 10 to 20% in older populations
- •Hotez cites the Kirkland nursing home, where 13 of about 100 people died
- 36:44 – 38:58
Hotez's Advocacy and the "Angel of Death" Testimony
Hotez recounts testifying to Congress and deliberately sounding the alarm about nursing homes, which prompted new precautions. He ties this to his career of combining vaccine science with advocacy on neglected diseases and against anti-vaccine misinformation.
- •He called the virus the "angel of death for older people" to provoke action
- •Nursing homes began stricter screening and preparedness reviews
- •HHS began mobilizing infection-control inspectors
- •He previously advocated for neglected tropical diseases
- •He wrote a book on his daughter's autism to counter anti-vaccine claims
- 38:58 – 44:46
Geographic Risk and the Coming Surge in Hospital Capacity
Hotez says any large US urban area is vulnerable and expects case counts to climb as testing expands. They discuss ICU capacity limits, seasonality uncertainty, and why the margin for error is small compared with Ebola.
- •Seattle, New Rochelle and New York City are showing spread, but any city could be affected
- •Expanded testing through Quest, LabCorp and Roche will reveal more cases
- •The next two weeks may be critical as hospital beds fill
- •Hospitals have slim margins and little excess capacity
- •Seasonality is unproven, and the virus is far more transmissible than Ebola
- 44:46 – 51:36
Models, Protecting the Elderly, and What to Watch Next
Responding to Marc Lipsitch's projection of widespread infection, Hotez calls it plausible while noting that models depend on assumptions. He discusses the hard tradeoffs of isolating older people, calls for specialized task forces, and names the data and vaccine trials he's watching.
- •Lipsitch's scenario of half the world infected in two years is plausible, but models hinge on assumptions
- •Isolating nursing home residents carries mental-health costs and difficult tradeoffs
- •Hotez wants specialized federal task forces beyond the overarching one
- •He is watching incidence and prevalence data as testing ramps up
- •He is also watching vaccine trials in Washington, where immune enhancement could appear
- 51:36 – 57:06
Closing Reflections on Public Communication
Hotez describes the difficulty of speaking across polarized networks and the need to keep updating his views as things change. He ends by praising Attia's public engagement as a counter to misinformation, and Attia thanks him.
- •Moving between media networks is politically tricky
- •New pathogens make early statements look wrong later
- •He wants daily briefings from the White House
- •He says scientists have been too inward-looking and public engagement counters misinformation
